Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of
morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in
the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits
sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study
examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.
Phase:
Phase 4
Details
Lead Sponsor:
Yamaguchi University Hospital
Collaborators:
Iwate Medical University Nakamura Memorial Hospital Ootemachi Hospital Tohoku University